Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

The interplay between bacillus Calmette-Guérin and Treg cells and its role to prevent or cure inflammatory diseases.

Lagranderie M, Guyonvarc'h PM.

Expert Rev Clin Immunol. 2014 Jun;10(6):741-5. doi: 10.1586/1744666X.2014.909286. Review.

PMID:
24837545
2.

Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, Thalmann GN.

Eur Urol. 2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.

PMID:
24674149
3.

Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis.

Ovchinnikova OA, Berge N, Kang C, Urien C, Ketelhuth DF, Pottier J, Drouet L, Hansson GK, Marchal G, Bäck M, Schwartz-Cornil I, Lagranderie M.

J Intern Med. 2014 Jan;275(1):49-58. doi: 10.1111/joim.12127. Epub 2013 Sep 12.

4.

Neonatal lung immune responses show a shift of cytokines and transcription factors toward Th2 and a deficit in conventional and plasmacytoid dendritic cells.

Roux X, Remot A, Petit-Camurdan A, Nahori MA, Kiefer-Biasizzo H, Marchal G, Lagranderie M, Riffault S.

Eur J Immunol. 2011 Oct;41(10):2852-61. doi: 10.1002/eji.201041224. Epub 2011 Aug 30.

5.

Mycobacterium bovis Bacillus Calmette-Guérin killed by extended freeze-drying reduces colitis in mice.

Lagranderie M, Kluge C, Kiefer-Biasizzo H, Abolhassani M, Nahori MA, Fitting C, Huerre M, Bandeira A, Bercovier H, Marchal G.

Gastroenterology. 2011 Aug;141(2):642-52, 652.e1-4. doi: 10.1053/j.gastro.2011.05.002. Epub 2011 May 14.

PMID:
21683076
6.

Cytosolic phospholipase A2alpha mediates Pseudomonas aeruginosa LPS-induced airway constriction of CFTR -/- mice.

Wu YZ, Abolhassani M, Ollero M, Dif F, Uozumi N, Lagranderie M, Shimizu T, Chignard M, Touqui L.

Respir Res. 2010 Apr 29;11:49. doi: 10.1186/1465-9921-11-49.

7.

Mycobacterium bovis bacillus Calmette-Guérin killed by extended freeze-drying targets plasmacytoid dendritic cells to regulate lung inflammation.

Lagranderie M, Abolhassani M, Vanoirbeek JA, Lima C, Balazuc AM, Vargaftig BB, Marchal G.

J Immunol. 2010 Jan 15;184(2):1062-70. doi: 10.4049/jimmunol.0901822. Epub 2009 Dec 9.

8.

Mycobacterium bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models.

Lagranderie M, Abolhassani M, Vanoirbeek J, Lefort J, Nahori MA, Lapa E Silva JR, Huerre M, Vargaftig B, Marchal G.

J Allergy Clin Immunol. 2008 Feb;121(2):471-8. Epub 2007 Nov 26.

PMID:
18037160
9.

Similar functional activity of dendritic cells recruited to the mesenteric lymph nodes of newborn and adult mice after the rectal delivery of Mycobacterium bovis BCG.

Abolhassani M, Lagranderie M, Caminshi I, Romain F, Balazuc AM, Wagner MC, Tanguy M, Fiette L, Sobhani I, Milon G, Marchal G.

Microbes Infect. 2006 Aug;8(9-10):2341-51. Epub 2006 Jul 12.

PMID:
16872860
10.

Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia.

Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, Chignard M, Si-Tahar M.

PLoS Pathog. 2006 Jun;2(6):e53. Epub 2006 Jun 9.

11.

In vivo efficiency of targeted norfloxacin against persistent, isoniazid-insensitive, Mycobacterium bovis BCG present in the physiologically hypoxic mouse liver.

Balazuc AM, Lagranderie M, Chavarot P, Pescher P, Roseeuw E, Schacht E, Domurado D, Marchal G.

Microbes Infect. 2005 Jun;7(7-8):969-75.

PMID:
15994108
12.

Targeted norfloxacin is active in vivo against persistent Mycobacterium bovis BCG.

Domurado D, Balazuc AM, Lagranderie M, Pescher P, Chavarot P, Roseeuw E, Coessens V, Stern S, Schacht E, Marchal G.

J Control Release. 2005 Jan 3;101(1-3):343-5. No abstract available.

PMID:
15838943
13.

Synthesis, degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin.

Roseeuw E, Coessens V, Balazuc AM, Lagranderie M, Chavarot P, Pessina A, Neri MG, Schacht E, Marchal G, Domurado D.

Antimicrob Agents Chemother. 2003 Nov;47(11):3435-41.

15.

Dendritic cells recruited to the lung shortly after intranasal delivery of Mycobacterium bovis BCG drive the primary immune response towards a type 1 cytokine production.

Lagranderie M, Nahori MA, Balazuc AM, Kiefer-Biasizzo H, Lapa e Silva JR, Milon G, Marchal G, Vargaftig BB.

Immunology. 2003 Mar;108(3):352-64.

16.

Development of mixed Th1/Th2 type immune response and protection against Mycobacterium tuberculosis after rectal or subcutaneous immunization of newborn and adult mice with Mycobacterium bovis BCG.

Lagranderie M, Balazuc AM, Abolhassani M, Chavarot P, Nahori MA, Thouron F, Milon G, Marchal G.

Scand J Immunol. 2002 Mar;55(3):293-303.

17.

Mixed immune response induced in rodents by two naked DNA genes coding for mycobacterial glycosylated proteins.

Garapin A, Ma L, Pescher P, Lagranderie M, Marchal G.

Vaccine. 2001 Apr 6;19(20-22):2830-41.

PMID:
11282194
18.

Effects of Mycobacterium bovis BCG on the development of allergic inflammation and bronchial hyperresponsiveness in hyper-IgE BP2 mice vaccinated as newborns.

Nahori MA, Lagranderie M, Lefort J, Thouron F, Joseph D, Winter N, Gicquel B, Lapa e Silva JR, Vargaftig BB.

Vaccine. 2001 Jan 8;19(11-12):1484-95.

PMID:
11163672
19.

Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes.

Abolhassani M, Lagranderie M, Chavarot P, Balazuc AM, Marchal G.

Infect Immun. 2000 Oct;68(10):5657-62.

20.

Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: malE.

Himmelrich H, Lo-Man R, Winter N, Guermonprez P, Sedlik C, Rojas M, Monnaie D, Gheorghiu M, Lagranderie M, Hofnung M, Gicquel B, Clément JM, Leclerc C.

Vaccine. 2000 Jun 1;18(24):2636-47.

PMID:
10781849
21.

Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice.

Lagranderie M, Chavarot P, Balazuc AM, Marchal G.

Vaccine. 2000 Jan 18;18(13):1186-95.

PMID:
10649619
22.

Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine.

Jackson M, Phalen SW, Lagranderie M, Ensergueix D, Chavarot P, Marchal G, McMurray DN, Gicquel B, Guilhot C.

Infect Immun. 1999 Jun;67(6):2867-73.

23.
24.

Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene.

Berthet FX, Lagranderie M, Gounon P, Laurent-Winter C, Ensergueix D, Chavarot P, Thouron F, Maranghi E, Pelicic V, Portnoï D, Marchal G, Gicquel B.

Science. 1998 Oct 23;282(5389):759-62.

25.

Cytotoxic activity induced by Mycobacterium Bovis BCG.

Gheorghiu M, Lagranderie M, Balazuc AM, Gicquel B.

Dev Biol Stand. 1998;92:199-208. No abstract available.

PMID:
9554276
26.

Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs.

Lim EM, Lagranderie M, Le Grand R, Rauzier J, Gheorghiu M, Gicquel B, Winter N.

AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1573-81.

PMID:
9430249
27.

Genetic control of antibody responses induced by recombinant Mycobacterium bovis BCG expressing a foreign antigen.

Lagranderie M, Lo-Man R, Dériaud E, Gicquel B, Gheorghiu M, Leclerc C.

Infect Immun. 1997 Aug;65(8):3057-64.

29.

Physical mapping of Mycobacterium bovis BCG pasteur reveals differences from the genome map of Mycobacterium tuberculosis H37Rv and from M. bovis.

Philipp WJ, Nair S, Guglielmi G, Lagranderie M, Gicquel B, Cole ST.

Microbiology. 1996 Nov;142 ( Pt 11):3135-45.

PMID:
8969511
30.

Stabilisation of BCG vaccines.

Gheorghiu M, Lagranderie M, Balazuc AM.

Dev Biol Stand. 1996;87:251-61. Review.

PMID:
8854025
31.

Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains.

Lagranderie MR, Balazuc AM, Deriaud E, Leclerc CD, Gheorghiu M.

Infect Immun. 1996 Jan;64(1):1-9.

32.

Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice.

Abdelhak S, Louzir H, Timm J, Blel L, Benlasfar Z, Lagranderie M, Gheorghiu M, Dellagi K, Gicquel B.

Microbiology. 1995 Jul;141 ( Pt 7):1585-92.

PMID:
7551026
33.

Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice.

Winter N, Lagranderie M, Gangloff S, Leclerc C, Gheorghiu M, Gicquel B.

Vaccine. 1995 Apr;13(5):471-8.

PMID:
7543715
34.
35.

Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen.

Lagranderie M, Murray A, Gicquel B, Leclerc C, Gheorghiu M.

Vaccine. 1993 Oct;11(13):1283-90.

PMID:
8296480
36.

BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route.

Lagranderie M, Ravisse P, Marchal G, Gheorghiu M, Balasubramanian V, Weigeshaus EH, Smith DW.

Tuber Lung Dis. 1993 Feb;74(1):38-46. Erratum in: Tuber Lung Dis 1993 Jun;74(3):217.

PMID:
8495019
37.

Identification of a Mycobacterium bovis BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria.

Romain F, Laqueyrerie A, Militzer P, Pescher P, Chavarot P, Lagranderie M, Auregan G, Gheorghiu M, Marchal G.

Infect Immun. 1993 Feb;61(2):742-50.

38.

Expression of Escherichia coli beta-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses.

Murray A, Winter N, Lagranderie M, Hill DF, Rauzier J, Timm J, Leclerc C, Moriarty KM, Gheorghiu M, Gicquel B.

Mol Microbiol. 1992 Nov;6(22):3331-42.

PMID:
1336563
39.

Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein.

Winter N, Lagranderie M, Rauzier J, Timm J, Leclerc C, Guy B, Kieny MP, Gheorghiu M, Gicquel B.

Gene. 1991 Dec 20;109(1):47-54.

PMID:
1756981
40.

Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs.

Lagranderie M, Frehel C, de Chastellier C, Gheorghiu M.

Biologicals. 1991 Oct;19(4):335-45.

PMID:
1665701
41.
42.

The effects of dispersed or surface grown cultures, manufacture and control methods on BCG standardization.

Gheorghiu M, Lagrange PH, Lagranderie M, Balazuc AM.

Dev Biol Stand. 1986;58 ( Pt A):191-205. No abstract available.

PMID:
3297863
43.

Resistance of high and low antibody responder lines of mice to the growth of avirulent (BCG) and virulent (H37Rv) strains of mycobacteria.

Gheorghiu M, Mouton D, Lecoeur H, Lagranderie M, Mevel JC, Biozzi G.

Clin Exp Immunol. 1985 Jan;59(1):177-84.

44.

[Rapid method of testing the viability of BCG vaccine by determination of ATP].

Gheorghiu M, Lagranderie M, Balazuc AM.

J Biol Stand. 1984 Jul;12(3):257-64. French. No abstract available.

PMID:
6480611
45.

[Effect of diffuse light and heat on 8 BCG vaccines prepared from 4 different strains].

Gheorghiu M, Lagranderie M, Balazuc AM.

Ann Microbiol (Paris). 1984 Mar-Apr;135A(2):263-70. French.

PMID:
6721327
46.

BCG-induced anaemia in mice: no direct effect of the growth of bacilli.

Milon G, Gheorghiu M, Lagranderie M, Lebastard M, Marchal G.

Ann Immunol (Paris). 1984 Mar-Apr;135C(2):195-204.

PMID:
6370092
47.

[Stability and immunogenicity of the fresh BCG vaccine applied with a new multiple puncture device (author's transl)].

Gheorghiu M, Lagranderie M, Bredèche M.

Ann Microbiol (Paris). 1981 May-Jun;132(3):307-18. French.

PMID:
7027870
48.

[Rapid assay of BCG vaccine viability by measuring the ATP content (author's transl)].

Gheorghiu M, Lagranderie M.

Ann Microbiol (Paris). 1979 Aug-Sep;130B(2):147-56. French. No abstract available.

PMID:
533067

Supplemental Content

Loading ...
Support Center